Boston, Mass.
From the Department of Plastic and Oral Surgery, Children's Hospital Boston, Harvard Medical School.
Plast Reconstr Surg. 2018 May;141(5):709e-717e. doi: 10.1097/PRS.0000000000004294.
Vascular anomalies currently are classified according to their clinical and histological characteristics. Recent advances in molecular genetics have enabled the identification of somatic mutations in most types of vascular anomalies. The purpose of this study was to collate information regarding the genetic basis of vascular anomalies.
The PubMed literature was reviewed for all citations that identified a mutation in a vascular anomaly between 1994 and 2017. Search terms included "vascular anomaly," "mutation," "gene," "hemangioma," "pyogenic granuloma," "kaposiform hemangioendothelioma," "capillary malformation," "venous malformation," lymphatic malformation," "arteriovenous malformation," and "syndrome." Articles that identified both germline and somatic mutations in vascular anomalies were analyzed. Mutations were categorized by type (germline or somatic), gene, signaling pathway, and cell(s) enriched for the mutation.
The majority of vascular anomalies had associated mutations that commonly affected tyrosine kinase receptor signaling through the RAS or PIK3CA pathways. Mutations in PIK3CA and G-protein-coupled receptors were most frequently identified. Specific types of vascular anomalies usually were associated with a single gene. However, mutations in the same gene occasionally were found in different vascular lesions, and some anomalies had a mutation in more than one gene. Mutations were most commonly enriched in endothelial cells.
Identification of somatic mutations in vascular anomalies is changing the paradigm by which lesions are diagnosed and understood. Mutations and their pathways are providing potential targets for the development of novel pharmacotherapy. In the future, vascular anomalies will be managed based on clinical characteristics and molecular pathophysiology.
目前,血管异常根据其临床和组织学特征进行分类。分子遗传学的最新进展使大多数类型的血管异常的体细胞突变得以识别。本研究的目的是整理有关血管异常遗传基础的信息。
对 1994 年至 2017 年间在 PubMed 文献中确定血管异常突变的所有引用进行了文献回顾。搜索词包括“血管异常”、“突变”、“基因”、“血管瘤”、“化脓性肉芽肿”、“卡波西样血管内皮细胞瘤”、“毛细血管畸形”、“静脉畸形”、“淋巴管畸形”、“动静脉畸形”和“综合征”。分析了确定血管异常中种系和体细胞突变的文章。突变按类型(种系或体细胞)、基因、信号通路和突变富集的细胞进行分类。
大多数血管异常都有相关的突变,这些突变通常通过 RAS 或 PIK3CA 途径影响酪氨酸激酶受体信号。PIK3CA 和 G 蛋白偶联受体的突变最常被发现。特定类型的血管异常通常与单个基因相关。然而,在不同的血管病变中偶尔会发现相同基因的突变,一些异常有一个以上基因的突变。突变最常富集在血管内皮细胞中。
血管异常体细胞突变的鉴定正在改变通过病变诊断和理解的模式。突变及其途径为开发新的药物治疗提供了潜在的靶点。在未来,血管异常将根据临床特征和分子病理生理学进行管理。